GLP-1 · Triple agonist (GIP/GLP-1/Glucagon) · weekly · investigational
Retatrutide
Retatrutide adds glucagon receptor activity on top of GIP/GLP-1, producing greater weight loss in trials. Still investigational; titrate conservatively.
Vial sizes
10 mg · 20 mg
Recommended BAC water
2 mL
Stable refrigerated
30 days
Titration schedule
| When | Dose | Units @ 5.0 mg/mL |
|---|---|---|
| Weeks 1–4 | 2 mg / week | 40.0 units |
| Weeks 5–8 | 4 mg / week | 80.0 units |
| Weeks 9–12 | 6 mg / week | 120.0 units |
| Weeks 13–16 | 8 mg / week | 160.0 units |
| Week 17+ | 12 mg / week (max studied) | 240.0 units |
Reconstitution example
For a 10 mg vial + 2 mL BAC water
Concentration
5.00 mg/mL
Per 0.1 mL (10 units)
0.50 mg
Doses per vial (avg)
1.7
What to watch for
- Glucagon activity can transiently raise heart rate — monitor resting HR weekly.
- Hydration matters more than with semaglutide/tirzepatide.
- Hold or step down if RHR rises >10 bpm above baseline.
Educational summary, not medical advice. Cross-reference current clinical literature and consult a licensed clinician before use.